Risperidone Shows No Benefit as Adjunctive Treatment for PTSD
Six-month treatment with risperidone showed no benefit over placebo in treating patients with military-related PTSD who were resistant to treatment with selective serotonin-reuptake inhibitor (SSRI) antidepressants, according to a report in August issue of the Journal of the American Medical Association. The study was a six-month, randomized, double-blind, placebo-controlled trial conducted from February 2007 to February 2010 at 23 Veterans Administration outpatient medical centers. Despite limited evidence supporting the practice, second-generation antipsychotics—of which risperidone is one—are commonly used for SSRI-resistant symptoms of PTSD, the authors say.
The content of Psychiatric News does not necessarily reflect the views of APA or the editors. Unless so stated, neither Psychiatric News nor APA guarantees, warrants, or endorses information or advertising on this site. Clinical information is not peer reviewed and thus should be independently verified.